Corcept Therapeutics Boosts Revenue Guidance on Strong Lifyorli Demand and Cushing’s Syndrome Growth — Corcept Therapeutics Incorporated

Event summary

Corcept Therapeutics reported Q2 2026 revenue of $256.1 million, up from $194.4 million in Q2 2025, driven by strong demand for Lifyorli and Korlym.
Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, generated $47.6 million in revenue in its first quarter of availability.
The company increased its 2026 revenue guidance to $1.1–$1.2 billion, citing continued strength in oncology and Cushing’s syndrome businesses.
Corcept resubmitted the New Drug Application (NDA) for relacorilant in Cushing’s syndrome with a PDUFA date of December 17, 2026.
Multiple clinical trials are ongoing, with results expected by the end of 2026 and 2027 across various indications including MASH and ALS.

The big picture

Corcept Therapeutics is capitalizing on the strong demand for its recently approved drug, Lifyorli, and the growing recognition of hypercortisolism in Cushing’s syndrome. The company's increased revenue guidance reflects its strategic focus on expanding into new indications and markets. The success of its clinical trials will be critical in determining its long-term growth potential in the competitive biotechnology sector.

What we're watching

Regulatory Approvals: Whether the FDA will approve relacorilant for Cushing’s syndrome by December 17, 2026, and the European Medicines Agency's decision on Lifyorli later this year.
Clinical Trial Results: The pace at which Corcept can deliver positive results from its ongoing trials in MASH, ALS, and various cancers by the end of 2026 and 2027.
Market Expansion: How Corcept will leverage the success of Lifyorli to expand into other oncology indications and sustain revenue growth.